ProCE Banner Activity

Rovalpituzumab Tesirine Safe, Active in Previously Treated SCLC

Slideset Download
Conference Coverage
In this phase I study, the antibody–drug conjugate rovalpituzumab tesirine demonstrated good response rates in patients with relapsed/refractory SCLC and high DLL3 expression, making it the first biomarker-directed therapy with activity in this disease.

Released: June 07, 2016

Expiration: June 06, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals